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Epigenetic regulationThe size and morphology of organs are largely determined by a genetic program. However in some cases, an
epigenetic mechanism inﬂuences the process of organ development. Particularly, epigenetic factors such as
hemodynamic stress and blood pressure affect the morphogenesis of cardiac chambers and valves. Here, we
report that the epigenetic inﬂuences affect the cardiomyocyte production. Taking advantage of longer
developmental period of medaka ﬁsh, we could examine the later emerging tissue responses to the defect of
ventricular beating, which occurred in the hozuki (hoz) mutant that harbors the mutated ventricular myosin
heavy chain (vmhc) gene. The mutant showed a remarkable ventricular enlargement, and we showed that
this enlargement was due to an excess production of ventricular cardiomyocytes in addition to the lack of
concentric chamber growth. By experimental blockade of blood ﬂow, we demonstrated that an elevated
cardiac pressure was responsible for the aberrant cardiomyocyte production. From these data, we propose
that the epigenetic tissue response to a stressed situation controls the production of cardiomyocytes to attain
a ﬁne tuning of heart formation.ami).
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
The formation of a functional vertebrate heart requires processes
that create proper morphology and size during embryonic develop-
ment. In particular, an adequate size and wall thickness of the heart
chambers are necessary for generating enough blood circulation for
the growth of the animal. For this, the heart increases its cell number
by cardiomyocyte proliferation, thickens the wall of its chambers by
the concentric growth in a direction perpendicular to the lumen, and
ﬁnally forms the highly trabeculated chambers. However, as the
cardiomyocyte proliferation ceases after embryonic development, the
postnatal increase in heart size occurs by the hypertrophic growth of
individual cardiomyocytes, the increase in the amount of intercellular
matrices, and the proliferation of non-muscle cells (Leu et al., 2001).
Only recently, it was reported that a fraction of adult cardiomyocytes
retain the potential for cell division (Beltrami et al., 2001; Bergmann
et al., 2009), but the number of dividing cells is less than 0.0005% of
total cardiomyocytes and less than 0.08% even when the heart is
injured by infarcts (Soonpaa and Field, 1997). Thus, the total number
of cardiomyocytes, which is critical for the heart to function as a
pump, is largely determined during embryonic development; and
accordingly any subtle abnormalities in cardiomyocyte proliferationand heart morphogenesis in the embryo may affect the homeostasis
and function of the postnatal heart.
A number of recent studies have suggested that both paracrine
factors from peripheral tissues such as the epicardium and endocar-
dium and autocrine factors secreted from the cardiomyocyte itself
support cardiomyocyte proliferation and chamber morphogenesis.
The action of retinoic acid (RA) and Erythropoietin (Epo) on
epicardiac cells produces paracrine growth factors such as Fibroblast
growth factors (Fgf) 9, 16, and 20; and the resultant activation of
downstream signaling pathways through the FGF receptor induces
the proliferation of myoblasts (Lavine et al., 2005). In parallel, Bmp10
has been proposed as one of the autocrine growth factors expressed
by the cardiomyocytes themselves. In Bmp10 knockout mice, an
apparent reduction in cardiomyocyte proliferation occurs, accompa-
nied by an increase in the level of P57Kip2, an inhibitory protein
against Cyclin-dependent kinase (Cdk; Chen et al., 2004). From the
analysis of conditional knockout of the transcription factor Nkx2.5 in
adult mice, it has been shown that Bmp10 function is also necessary
for the trabecular muscle growth in postnatal stages (Pashmforoush
et al., 2004). Furthermore, additional signaling pathways including
the Reptin and Pontin (Rottbauer et al., 2002) and the L-type calcium
channel (Rottbauer et al., 2001) are also involved in the regulation of
cardiomyocyte proliferation during development. In addition to these
positive regulators, a study in mice has identiﬁed a negative regulator
for cardiomyocyte proliferation, Jumonji, which is required for the
cessation of cardiomyocyte proliferation in postnatal stages (Toyoda
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cardiomyocyte proliferation is terminated, and the mutant mice dis-
play an elevated expression of cyclinD1 and aberrant proliferation of
their cardiomyocytes.
In addition to the cardiomyocyte number, another important pro-
cess for making a functional heart is the formation of its thick-layered
chambers. During the early stage of heart development, a thin-layered
cardiac wall grows within a planar direction; however, at an appro-
priate stage of heart development, the cardiomyocyte changes the
polarity of cell divisions and adds new cells in the myocardium in a
direction perpendicular to the lumen to attain the concentric growth.
Three zebraﬁsh mutants with defective concentric growth of heart
chambers, heart of glass, santa, and valentine, have been isolated by a
mutant screening (Mably et al., 2003; Mably et al., 2006). Analyses of
them have identiﬁed a novel signaling pathway for concentric growth,
in which the Heart of glass protein in the endocardium regulates
the concentric growth of the myocardium. Additionally, the endocar-
dium also plays a role in the trabeculation of the heart chambers;
i.e., Neuregulin (Nrg), a molecule secreted from the endocardium, is
necessary for the trabeculation by acting through its receptors, ErbB2
and ErbB4, in themyocardium (Gassmann et al., 1995; Lee et al., 1995;
Meyer and Birchmeier, 1995).
Thus, cardiomyocyte proliferation and formation of a thick
chamber wall are largely regulated by genetic factors. However, in
addition to such genetic factors, recent studies have suggested that
epigenetic factors also inﬂuence heart formation. For example, in the
zebraﬁsh mutant weak atrium (wea), which has a nonsense mutation
in the atriummyosin heavy chain (amhc) gene, the ventricle formation
is adversely affected due to the defective heartbeat in the atrium
(Berdougo et al., 2003). The silent heart (sih)/cardiac troponin T and
cardiofunk (cfk)/sarcomere actin mutants, whose heartbeat is com-
pletely impaired, show a defect in endocardial cushion (EC) formation
(Sehnert et al., 2002; Bartman et al., 2004). Moreover, analysis using
the wea and half-hearted (haf)/ventricle myosin heavy chain (vmhc)
mutant zebraﬁsh has suggested that the blood ﬂow affects the
regional cell-shape changes of cardiomyocytes and the resulting
formation of the ventricular curvature (Auman et al., 2007). Thus,
epigenetic factors such as the heartbeat and blood ﬂow inﬂuence
heart morphogenesis. However, it has not been documented in detail
whether or not the epigenetic factors also inﬂuence other aspects of
heart morphogenesis such as the cardiomyocyte production and
concentric chamber growth.
Here we report that the defective ventricular heart beat in the
medaka mutant hozuki (hoz), which has a nonsense mutation in the
vmhc gene, affected the concentric chamber growth and the number
of cardiomyocytes in the ventricle. We show that an elevated cardiac
pressure causes the excess production of cardiomyocyte. Our data
thus suggest the existence of an epigenetic response mechanism that
tunes the production of ventricular cardiomyocytes in response to an
altered physiological condition.Methods
Fish strains and maintenance
Medaka ﬁsh (Oryzias latipes) of wild type strains, Cab and HNI,
were maintained at 28.5 °C in a re-circulating systemwith a 14-h/day
and 10-h/night cycle. The medaka heart mutant hozuki (hoz), a
Japanesewordmeaning “ground cherry,”was isolated by our previous
mutant screening (Sakamoto et al., 2004). Collected fertilized eggs
were incubated at 28.5 °C in medaka Ringer's solution (0.65% NaCl,
0.04% KCl, 0.011% CaCl2, 0.01% MgSO4, 0.01% NaHCO3, and 0.0001%
methylene blue), and developmental stages were determined by their
morphology according to the medaka stage table described by
Iwamatsu (2004).Genetic mapping and positional cloning
Genetic mapping was performed according to the method
described earlier (Kimura et al., 2005). Brieﬂy, a hoz mutant on the
cab genetic background was crossed with the HNI strain to obtain the
genetically polymorphic F1 offspring. These F1 ﬁsh were crossed to
obtain the hoz mutant embryos for mapping. The pooled bulked
segregant analysis was performed to localize the hozmutation on the
medaka linkage group (LG) (Postlethwait and Talbot, 1997). Further
mapping was done by using custom-designed markers based on the
sequence polymorphism between the cab and HNI strains. The
following mapping primers and restriction enzymes were used for
mapping:MF01SSA019D03 F: 5′-AAAGGCATCATTACTGGTGT-3′,
R: 5′-ACAACTAACTATGGGTCCTG-3′;ZPC2-3 F: 5′-GCATTCCTTCCTGCCTGACC-3′,
R: 5′-AAAGTGGTTACAAGAGGGAGG-3′ (NdeI);MF01SSA041A11 F: 5′-GTTCAGTGATCCCGTCAATGC-3′,
R: 5′-CTATCCGAAGAGTACAGCAGG-3′ (Dde I);MAP4 F: 5′-CGCTTTTCAGGTCCACCGTTT-3′,
R: 5′-CGTCTGGTTCCAACAAGGCTG-3′.The coding sequence of vmhc cDNA was deposited in the
GenBank/DDBJ DNA sequence database under an accession number
AB515306.
Whole-mount RNA in situ hybridization (ISH) analysis
Whole-mount ISH analysis was performed according to the pro-
cedure described previously (Thisse and Thisse, 2008). After staining,
tissues were ﬁxed with 4% paraformaldehyde (PFA) in phosphate-
buffered saline (PBS) for color preservation, equilibrated with 80%
glycerol, andmounted on slide glasses for microscopic observation. The
following primers were used for cloning the respective probes:
vmhc F: 5′-GCTGAGATGTCCGTGTATGGTGC-3′, R: 5′-GCTCCTCAC-
GAGGCCTCTGCTTG-3′;
mhc2 F: 5′-TCAGATCACACGGATTATGG-3′, R: 5′-ATGGCAGAGGGG-
TATCCACC-3′;
amhc F: 5′-TGCACTGATGGCTGAATTTG-3′, R: 5′-ACTTGATCTA-
CACCTTGGCC-3′;
cmlc2 F: 5′-AATGTCTTTTCCATGTTTGAGC-3′; R: 5′-CTCCTCTTTCTC-
ATCCCCATG-3′;
nkx2.5 F: 5′-CCAGCACGTCCACTCCTTTC-3′, R: 5′-TCACCACGTCC-
TAATGCCG-3′;
bmp10a F: 5′-CATCCGCAGCTTTAAGAACG-3′, R: 5′-TACAGCAGG-
GAGATGGGGTC-3′;
bmp10b F: 5′-TCATGCTGGAGCTCTACAATCG-3′, R:5′-CGCATTC-
TGCTACTACCATTCC-3′;
bnp F: 5′-CACAACAGACCGGAACCAGAACC-3′, R: 5′-GGGACGATC-
TGGACAGTGGG-3′;
jarid2/jumonji F: 5′-CCAACACAAATGCATTTACAAGG-3′, R: CGTAG-
CGAGCAGAAGAGAGC-3′;
tsc2 F: 5′-TACCAGCCGAGCAATGAGG-3′, R: GCCAGGTCCTTGTCTT-
CAGC-3′;
epo F: 5′-GCTGTTGATTGTGTTGGAGTGG-3′, R: CGCAGGAAGTT-
CACGTGG-3′;
nrg1 F: 5′-GAATTTACTGGTGATCGCTGCC-3′, R: AAAGCGACTGACGG-
GACG-3′.
The respective products ampliﬁed by the polymerase chain
reaction (PCR) were subcloned into standard vectors and used for
synthesizing the digoxigenin (dig)-labeled RNA probes.
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Transmission electron microscopy (TEM) analysis was performed
according to themethod described earlier (Rottbauer et al., 2001). The
parafﬁn embedding and sectioning were performed according to a
standard method using Bouin's ﬁxative. Embedded samples were
serially sectioned with a microtome; and the sections were mounted
on slide glasses, washed with xylene and ethanol, and stained with
hematoxylin and eosin.
Immunohistochemistry
Medaka whole embryos or dissected hearts were ﬁxed by the
following procedures. For staining withMF20, an antibody against the
myosin heavy chain (Developmental Studies of Hybridoma Bank),
embryos were ﬁxed with the IHC Zinc Fixative (BD Biosciences) at
room temperature for 20 h. For staining β-catenin (C2206, Sigma),
ﬁxation was donewith 80%methanol, 20% dimethylsulfoxide (DMSO)
at room temperature for 2 h followed by dehydration with methanol
at −30 °C. For phalloidin (Invitrogen) staining of F-actin bundles,
dissected hearts were ﬁxed with 4% PFA in PBS for overnight at 4 °C.
Following ﬁxation and removal of the egg chorion, samples were
equilibrated with PBS containing 0.1% Triton X-100 (PBSTx) and
further replaced with PBSTx containing 1% DMSO (PBSTxD). Samples
were blocked with 2 mg/ml BSA and 5% serum in PBSTxD for 2 h at
room temperature and reacted with the above antibodies at 4 °C for
overnight. The MF20, anti-β-catenin, and Alexa568-conjugated
phalloidin were used at 1:100, 1:1500, and 1:1000 dilutions,
respectively. After washing with PBSTxD, the respective secondary
antibodies were applied at room temperature for 2 h at 1:1000
dilutions. After washing, samples were mounted in 80% glycerol
supplemented with 2.5% 1,4-diazabicyclo [2,2,2] octan (DABCO) as an
antifade agent and viewed under a confocal microscope, Fluoview
FV1000 (Olympus).
Measurement of ventricle size and the estimation of surface area
The lengths of long (L) and short (S) axes of wild type and hoz
mutant ventricles at stage 37weremeasured from confocal pictures of
ﬁxed and dissected hearts. We approximated the ventricle shape as a
spheroid, and the surface areas were calculated from the following
equation:
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a, b, and c are themajor andminor axes of the spheroid; and in this
case, a=L/2 and b=c=S/2.
BrdU analysis
The cell proliferation analysis was conducted after labeling
embryos with BrdU for 20 h starting at stage 34. After incubation
in 2 mM BrdU at 28.5 °C, embryos were ﬁxed with 4% PFA for 2 h
at room temperature. The ﬁxed embryos were dehydrated with
methanol and stored at −20 °C. Immunochemical detection was
conducted by the procedure described recently (Yoshinari et al.,
2009). The BrdU-labeled ﬂuorescent cells were quantiﬁed from theacquired images obtained by a confocal microscopy (Fluoview
FV1000, OLYMPUS). We routinely dissected the heart, mounted in
an orientation that the ventricle and atrium boundary is clearly
visible. More than 100 optical sections were obtained from each heart,
and generate the partially stacked images by merging every 20–40
sections. Cell count was carefully performed on these optical slices to
exclude the BrdU-labeled cells in non-muscle tissues.
Generation of transgenic ﬁsh and cell count
The construct that drives the expression of DsRed2-nuc under the
control of the zebraﬁsh cmlc2 promoter was a gift from G. C. Burns
(Mably et al., 2003). This construct was injected into fertilizedmedaka
eggs at the 1-cell stage at a dose of 10–40 ng/μl. Embryos with bright
ﬂuorescence in the heart were raised, and a stable germ line
transmission was established. The resulting transgenic strain was
used for scoring the cardiomyocyte numbers in the ventricle. The wild
type and hoz mutant hearts carrying the Tg (cmlc: DsRed2-nuc) were
dissected, ﬁxed with 4% PFA in PBS for 10 min at room temperature,
and mounted in 1% agarose gel. We routinely made 50–100 optical
sections from one heart sample, and cell count was conducted on the
merged images of every 25 sections.
2,3-butanedione monoxime (2,3-BDM) treatment
We tested a series of 2,3-BDM concentrations on medaka ﬁsh at
stage 32. Concentrations higher than 30 μM showed a toxic effect
within 24 h; however at concentrations lower than 15 μM, the reagent
could not effectively block the heartbeat. For the healthy survival
of medaka ﬁsh and complete block of heartbeat, we adopted the
2,3-BDM treatment at 22.5 μM for 24 h and 17.5 μM for the fol-
lowing 48 h. Under this condition, the ventricle did not beat, but
the atrium showed an occasional and weak beating. In some wild type
embryos, the accumulation of blood cells in the atrium was observed,
but it did not affect the number of ventricular cardiomyocytes.
RT-PCR analysis
Hearts were harvested from wild type and hoz mutant embryos
(n=40 for each) at stage 37. Total RNAs were extracted and 5 μg
of total RNA was used for cDNA synthesis. The primers for bnf and
bmp10 were the same as those used for cloning the in situ probes.
ef1α was ampliﬁed with primers: F, 5′-ATCGTTGCTGCTGGTGTTG-3′;
R, 5′-AGGCGATGTGAGCTGTGTG-3′, as an internal control. The PCR
reaction comprised 94 °C for 30 s, 55 °C for 30 s, and 72 °C for 30 min.
Results
Enlarged ventricle in the medaka hoz mutant
In the previous screening for ENU-induced mutations of medaka
ﬁsh, we identiﬁed several mutants with phenotypes showing
abnormal heart development. The hoz mutant was a recessive lethal
mutant having an abnormally large ventricle. Initial formation of the
hoz heart tube appeared to be normal until medaka developmental
stage 30, a stage that corresponds to the cardiac looping stage
(Fig. 1C). However in the subsequent stages of development, their
ventricles progressively enlarged (Figs. 1A, B). Despite this abnor-
mality, the mutant survived until 8 dpf, a stage around hatching, in a
relatively healthy condition without forming pericardiac edemas.
Observations of the hoz ventricle showed that ventricular con-
traction was inhibited when the ventricle and atrium are segregated
at stage 26 (see Supplementary Videos 1 and 2). The blood ﬂow was
clogged in the ventricle due to the sustained beating of the atrium,
although a very slow stream of blood ﬂow could be seen at stage 37
(data not shown). It is therefore believed that ventricular
Fig. 1. Ventricle enlargement of the medaka hozmutant. (A, B) Morphology of wild type and hozmutant heart at stage 37. The mutant showed a unique phenotype that the ventricle
(V) was extraordinary enlarged and ﬁlled with blood cells (panel B) , whereas the mutant atrium (A) had a normal appearance (panel A). Due to inability of heart beating in the
ventricle (see Videos S1, S2 in the supplementary material), the blood ﬂow was very slow and almost clogged around stage 34. (C) A diagram comparing developmental stages of
medaka ﬁsh and zebraﬁsh. Themedaka developmental stages (top) and the corresponding zebraﬁsh stages are aligned (bottom), in which the key events of heart morphogenesis are
indicated in the middle. Though the zebraﬁsh heart mutants with defective beating (Sehnert et al., 2002; Berdougo et al. 2003; Bartman et al., 2004; Auman et al., 2007; Rottbauer
et al., 2007) have been mainly analyzed within 48 hpf (highlighted with green), the hozmutant showed a characteristic ventricle enlargement phenotype at the later stage of heart
development (highlighted with pink), which was possibly due to its longer survival until 8 dpf in a relatively healthy condition without the formation of pericardiac edemas. The
scale bar represents 100 μm in (A).
Table 1
Heart beating rate of wild type embryos and hoz mutant.
Heartbeat at stage 30 n Heartbeat at stage 37 n
Wild type 137±5 7 157±4 4
hoz mutant 136±5 7 152±2 4
Quantitative analysis of heart beating (per minute) at stage 30 and stage 37 at 28.5 °C is
shown. Measurement was performed by using the recorded movies. The rate in hoz
mutant was measured by the atrial beating.
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of the defect of blood ﬂow, the overall number of blood cells appeared
similar between wild type and mutant embryos during stages 30–39
(data not shown), suggesting that the overall hematopoiesis was not
affected in the hoz mutant. Furthermore, the beat rate of the hoz
atrium did not show signiﬁcant alteration at stage 37 (Table 1), a stage
when the enlargement of the hoz ventricle became maximum. In
comparison to the ventricle, the size of the hoz atrium was never
affected (Fig. 1B).
Comparing with similar zebraﬁsh heart mutants with defective
beating (Sehnert et al., 2002; Berdougo et al. 2003; Bartman et al.,
2004; Auman et al., 2007; Rottbauer et al., 2006), which have been
mainly analyzed within 48 hpf of zebraﬁsh development (highlighted
with green in Fig. 1C), the hoz mutant showed a characteristic
enlargement of the ventricle at later stages of heart development
(highlighted with pink in Fig. 1C). Thus, the hoz mutant has a unique
later heart phenotype that occurs late in development, likely due to
secondary defects caused by the abnormal ventricular contractions.
Loss-of-function mutation in the ventricle myosin heavy chain
(mhc1/vmhc) gene in the hoz mutant
To explore the molecular basis of the hoz mutant, we determined
the responsible gene. Genetic mapping localized the hoz locus to
medaka linkage group 17, a region located between ZPC2 and
MF01SSA041A11 (Fig. 2A). By further ﬁne mapping, we identiﬁed agenomic sequence contig of approximately 250 kb length, the entire
region of which showed zero recombination with the hoz locus
(Fig. 2A). The contig contained 4myosin heavy chain (mhc) genes, one
of which had a strong sequence homology with the vmhc gene of
zebraﬁsh and other species.
To further narrow down the candidates, we examined the ex-
pression of all 5 genes on the contig by in situ RNA hybridization and
found that only the vmhc-like gene (mhc1 in Fig. 2A) , but not other
4 genes, had an exclusive expression in the ventricle (Fig. 2B),
suggesting the mhc1/vmhc gene was most likely to be the hoz gene.
The second gene mhc2, which corresponded to the mMYHC1 gene
reported by Ono et al. (2006) (GenBank AB256934), was expressed in
the slow skeletal muscle of the somites (data not shown).
Given the unique expression of mhc1/vmhc gene in the ventricle,
we focused on this gene and performed further analysis. The sequence
Fig. 2. Identiﬁcation of hozmutation in the vmhc gene. (A) Genetic mapping of hoz locus on the medaka linkage group 17. The hoz region was located between the ZPC2 (GenBank
AF331672) and MF01SSA041A11 (GenBank BJ002936) (upper). Further ﬁne mapping narrowed down the hoz locus within a genomic DNA contig with ∼250 kb length, which
containing 4 copies of myosin heavy chain genes were clustered (lower). No recombinationwas detected in the entire region of the contig. (B) in situ hybridization analysis detecting
mhc1/vmhc RNA in the wild type and hoz mutant ventricle at stage 30. The mhc1/vmhc mRNA was down-regulated in the hoz mutant. (C) A nonsense mutation identiﬁed in the
mhc1/vmhc gene, which changed the lysine residue at position 993 to a stop codon. (D) Structure of the ventricle myosin heavy chain (Vmhc) protein and the position of the
nonsense mutation in the hozmutant. (E) Absence of Myosin heavy chain (Mhc) protein in the mutant ventricle at stage 34 as revealed by staining with MF20, a pan-Mhc antibody.
Staining was seen in the ventricle and atrium of wild type embryos (WT), but absent in the ventricle of the hoz mutant (hoz). The scale bar represents 100 μm in (B) and (E).
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middle of its protein-coding region (Fig. 2C), resulting in the loss of
most of themyosin tail domain, which is necessary for the assembly of
myosin heavy chains to form their coiled-coil structure (Fig. 2D).
Intriguingly, we found that the expression ofmhc1/vmhcwas severely
down-regulated in the hoz mutant (Fig. 2B), possibly due to the
mechanism known as nonsense-mediated RNA decay. We also
conﬁrmed that the hoz ventricle did not contain the Mhc proteins
by staining with the pan-myosin heavy chain antibody, MF20
(Fig. 2E), supporting that there was no compensatory expression of
other myosin heavy chains in the ventricle and that the identiﬁed
mutation in the mhc1/vmhc is the cause of loss of ventricle beating.
Although we could neither succeed in producing the phenocopy
by the morpholino antisense oligonucleotide (MO) nor rescue the
hoz phenotype with mRNA injection due to the late hoz phonotype
(3–4 dpf), from these supporting evidences, we concluded that the
hoz mutation resulted in the complete loss of myosin heavy chain
function in the ventricle.
Effect of vmhc mutation on cardiomyocyte differentiation
and maturation
We next examined how the heart formation and maturation is
affected by the loss of Vmhc function and heart contraction. We
evaluated the cardiomyocyte differentiation in the hoz mutant by
looking at the expression of genes such as nkx2.5, tbx5, and mef2c
(Olson, 2006), transcription factors whose products are required for
heart development and cardiomyocyte differentiation. However, no
signiﬁcant alteration of their gene expression was observed in the hoz
heart primordium (Supplementary Figs. 1A–C), suggesting that the
heart-ﬁeld formation and cardiomyocyte differentiation occurrednormally in the hoz mutant. As well as the regulatory transcription
factors, the expression of cmlc2 and amhc, genes encoding the
myoﬁbril proteins in the entire heart and atrium, respectively, were
neither affected in the hoz mutant (Supplementary Figs. 1D, E).
Given the normal differentiation of ventricular cardiomyocytes,
we next asked whether or not they matured normally as cardiac
muscle cells. To examine the maturation status of ventricular myo-
cytes, we examined their subcellular structures by electron micros-
copy analysis. In contrast to the thick myoﬁbrils seen in the wild
type ventricular cells (see arrow in Fig. 3A), the hoz ventricular cells
lacked the myoﬁbrils and contractile apparatus (Fig. 3B). However,
despite the lack of myoﬁbrils, the mutant ventricular cells retained a
number of mitochondria as in the wild type cardiomyocytes (Figs. 3A,
B; arrowheads) and stored a number of dense glycogen particles
in their cytoplasm (Fig. 3B), suggesting that the cardiomyocyte
maturation process somehow occurred in the hoz ventricle. On the
other hand, we did not see any abnormalities in the atrial myocytes
(data not shown).
Defective chamber morphogenesis in the hoz ventricle
A previous study by Auman et al. (2007) on zebraﬁshmutantswith
altered amhc and vmhc genes suggested that cardiac contractility and
blood ﬂow are required for proper cell-shape changes and the
formation of chamber curvature during heart morphogenesis. In the
hoz mutant, we visualized the cell shape by staining with anti-β-
catenin antibody (Supplementary Figs. 2A–D) and observed that
the ventricular cardiomyocyte in the hoz mutant is also expanded
within the planar dimension and have irregular but hexagonal shapes
as in the zebraﬁsh vmhc mutant (Auman et al., 2007; Supplementary
Fig. 2D). In addition, the phalloidin staining showed that the
Fig. 3. Normal differentiation and maturation of hoz ventricular cardiomyocytes.
(A, B) Examination of subcellular structure of wild type (A) and mutant (B) ventricular
cells at stage 37 by transmission electron microscopy. Thick myoﬁber bundles were
seen in the cardiomyocytes of the wild type embryo (arrow), but not in those of the hoz
mutant. Arrowheads indicate the well-developed mitochondria, a hallmark of mature
cardiac muscles. Both in wild type and mutant, many glycogen granules, which are also
a sign of mature cardiomyocytes, were present within the ventricular cardiomyocytes.
A high-magniﬁcation view of glycogen granules (boxed area in B) is shown in the upper
right corner. The observations were conﬁrmed by examining more than 90 sections
through the heart region from each of 3 wild type and 2 mutant embryos. n, nucleus.
The scale bar represents 1 μm in (A).
35Y. Taneda et al. / Developmental Biology 340 (2010) 30–40formation of contractile F-actin cables, which are associated with
myosin heavy chains, was missing in the hozmutant (Supplementary
Figs. 2E, F), indicating that the loss of myosin heavy chain affects the
formation of F-actin bundles.
In addition to such a phenotype in the cardiomyocyte cell shape,
we found that the concentric chamber growth was also impaired.
Following the stage of cardiac looping and the formation of curvature,
the cardiac chambers increase thickness of the wall through the
concentric growth, and give rise to the trabeculated chambers in the
adult animal. The concentric growth of the ventricular wall begins in
medaka ﬁsh at stage 34, when the wall thickness is 1–2 cell layers
(Fig. 4A). By stage 36, 3–4 layers of cardiomyocytes can be recognized
(Fig. 4C). In the hozmutant, the ventricular wall was also 1–2 layers at
stage 34 and remained so at stage 36 (Figs. 4B, D), even after stage 37.
To further conﬁrm this phenotype, we utilized the Tg (cmlc2:DsRed2-
nuc) embryo, in which the identity of cardiomyocytes was visible by
the expression of DsRed2 in the nucleus, and revealed that the lack of
cardiomyocyte layers indeed occurred in the hozmutant (Figs. 4E, F).
Thus, the loss of Vmhc function affected the concentric chamber
growth in the later phase of heart development.
Excess production of cardiomyocytes in the hoz ventricle
As we have shown in Fig. 1B, the hoz ventricle was strikingly
enlarged. We suspected that merely the cell-surface expansion and
lack of concentric growth could not account for it. Indeed, according to
our estimation (Fig. 5A), the surface area of the hoz ventricle was
approximately 6 times greater than that of the wild type one at stage
37 (Fig. 5B). Taking the decrease of concentric growth in account,
which increases the surface area by 2 times, there was still a 3-fold
increase in the surface area. Judging from the spacing of cardiomyo-cyte nuclei (Figs. 4E, F), the expansion of each cell surface may not be
as big as 3 times. Therefore, we suspected that an increase in cell
number might have been responsible for the ventricular enlargement.
We examined cell proliferation by labeling with BrdU during
stages 34–36 (Fig. 5C). Though it has been suggested that the
cardiomyocyte proliferation rate is relatively low before the heart
looping stage in chick and zebraﬁsh (Soufan et al., 2006; de Pater et al.,
2009), the rate after the looping stage (Fig. 1C) appeared to be higher,
possibly due to the rapid increase of the thickness of chamber wall.
We indeed observed that a number of BrdU-labeled cells were present
in the entire chamber wall region of the wild type heart by examining
the confocal optical sections. Using the confocal images, we carefully
counted the BrdU-labeled cells within the cardiomyocyte layers and
revealed a detectable increase of the number of BrdU-positive cells
(∼1.4 fold) in the hoz ventricle (Fig. 5D), although the statistical
signiﬁcancewas not sufﬁcient (Pb0.1), whichwas probably due to the
higher number of proliferating cardiomyocytes in this stage and
inevitable count of the endocardium and blood cells.
To precisely determine the number of cardiomyocyte, we used the
Tg (cmlc2:DsRed2-nuc), expressing DsRed in the cardiomyocyte nuclei
(Figs. 5E, F). As in the BrdU analysis, we quantiﬁed the number of
cardiomyocytes by using confocal images and found that the hoz
mutant ventricle displayed a signiﬁcant increase in the number of
cardiomyocytes comparedwith thewild type ventricle at stage 34 and
stage 37; whereas the difference was not evident at stage 30 (Fig. 5F).
Such increase was more evident at stage 37 (wild type: 261±20; hoz
mutant: 413±16). Therefore, the number of cardiomyocytes in the
hoz ventricle increased more than 1.5 times than that of the wild
type one. Since the number of cardiomyocytes in wild type embryos
was 332±20 (n=4) even at stage 39, 2 days after stage 37, we
concluded that an excess number of cardiomyocytes were added in
the hoz ventricle during later phase of heart development. In contrast
to the increase of ventricular cardiomyocyte, we did not see any
detectable alterations in cardiomyocyte number, shape and size in the
atrium, although we did not perform an accurate quantiﬁcation.Induction of bnp and bmp10 family gene expression in the hoz ventricle
in response to the increased cardiac pressure
Progressive enlargement of the ventricle often accompanies
elevated cardiac pressure. We therefore investigated whether the
loss of ventricular beating caused a stress on the developing ventricle.
To evaluate the stressed status of ventricle, we looked at the ex-
pression of natriuretic peptide genes. As a modulator of cardiac
function, this family of proteins, which is induced in the hypertrophic
and dilated cardiomyopathies of mammals, is known to be the most
powerful neurohumoral predictor of left-ventricular function and
prognosis (Cameron and Ellmers, 2003; Clerk et al., 2007). Though the
atrial natriuretic peptide (anp) gene is widely used as a marker for
cardiac stress, medaka ﬁsh does not have an exact ortholog (Inoue et
al., 2003; our database search). Instead, we used the brain natriuretic
peptide (bnp) gene, which is also known to have similar functions and
to be induced by physiological stresses (Tokola et al., 2001; Cameron
and Ellmers, 2003). The results of in situ expression and RT-PCR
analysis showed that the expression of bnpwas strongly elevated only
in the ventricle (Figs. 5G, H), conﬁrming that the hoz ventricle was
exposed to a stressed status.
We next examined the expression of molecules such as tsc2
(Pasumarthi et al., 2000), epo (Stuckmann et al., 2003), nrg1 (Ford et
al., 1999), jarid2/jumonji (Toyoda et al., 2003), fgf2 (Sheikh et al.,
1999), raldh2 (Keegan et al., 2005; Wills et al., 2008), and bmp10
(Chen et al., 2004) that are implicated in the regulation of heart
growth. Among them, only the expression of the bmp10a and bmp10b
genes exhibited apparent up-regulation in the hoz ventricle (Figs. 5G,
H), while bmp10a showed a weaker expression (data not shown).
Fig. 4. Impaired concentric layer growth of ventricular chamber in the hozmutant. (A–D) Histological analysis of the ventricular wall in wild type (A, C) and hoz (B, D) ventricles at
stage 34 (A, B) and stage 36 (C, D). Parafﬁn sections were counter-stained with hematoxylin and eosin. The hoz ventricle was ﬁlled with blood cells, most of which were nucleated
red blood cells (RBC). The concentric growth of the ventricular wall was not evident at stage 34 (A, B). But at stage 36, 3–4 cells layers were apparently observed (C), whereas the
ventricular wall of the hozmutant remained 1–2 layers at this stage (D). (E, F) Confocal optical sections of ventricular chambers of wild type (E) and hoz mutant (F) at stage 37, in
which the cardiomyocytes were visualized by the Tg (cmlc2:DsRed2-nuc). The defect in concentric growth of cardiomyocyte layers is clearly observed in the hoz ventricle. The scale
bar represents 50 μm in (A). All pictures are at the same magniﬁcation.
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elevated cardiac pressure
It has been proposed that intracardiac hemodynamics and blood
pressure act as a key epigenetic factor in embryonic cardiogenesis
(Hove et al., 2003). Therefore, we next examined whether or not the
increase in cardiomyocyte number in the hoz mutant depended on
the elevated cardiac pressure caused by the inability of ventricular
beating. In order to dissect the effect of cardiac pressure, the
morpholino antisense oligonucleotide against troponin Twas success-
fully used to abolish the heartbeat in zebraﬁsh (Sehnert et al., 2002);
however it could not be applied to reduce the heart beating in medaka
ﬁsh due to the long developmental period. In this study, we ﬁrstly
adopted an approach to manipulate the blood ﬂow without affecting
myocardial function. In contrast to the zebraﬁsh, the veins in medaka
ﬁsh that ﬂow into the sinus venosus (SV) are arranged into 3 major
ducts, i.e., the 2 common cardinal veins (CCV) located laterally and the
marginal vein (MV) from the caudal region (Fig. 6A; Fujita et al.,
2006). By ﬁrmly pinching and crushing these veins with forceps at
stage 32, we succeeded in blocking the blood ﬂow (Figs. 6B, C).
Such an operation could reduced the blood inﬂow into the atrium;
and the ﬂuid between the ventricle and operated sites moved back
and forth, resulting in the alleviation of excess blood pressure in the
hoz mutant. In the hoz embryos in which blood ﬂow was not presentFig. 5. Aberrant increase in number of cardiomyocytes in the hoz ventricle. (A)Measurement
estimated from the average lengths of the long (L) and short axes (S). BA, bulbus arteriosus; V
was performed based on the measurement of long and short axes of ventricle (A) according t
Statistical signiﬁcance was tested by using Student's t-test. *Pb0.01. (C) Confocal stacked im
was detected by the anti-BrdU antibody staining. (D) Quantiﬁcation of BrdU-labeled cells. C
regions such as the blood cells and endocardial cells. Data are presented as the mean±SEM
n=9 for hoz). (E) Confocal stacked images of wild type and hozmutant hearts that harbor th
in which approximately half of the cardiomyocytes are visible. (F) Quantiﬁcation of ventr
confocal images. Data are presented as the mean±SEM. Statistical signiﬁcance was tested by
respectively). *Pb0.01 (n=5 for WT and hoz, respectively, at stage 34; n=7 for WT and n=
elevated cardiac pressure. In situ RNA hybridization analysis (G) detected the strong expres
ventricle (V), whereas only a faint expression was detected in wild type. RT-PCR analysis of
(M) embryos at stage 37 (H) quantitatively supported the induction of bnp and bmp10b in
27 cycles for bmp10b, and 23 cycles for ef1α. V, ventricle; A, atrium. The scale bar represenat stage 37 (3 of 7 operated embryos), the average number of
cardiomyocytes (239 cells; Fig. 6E) was comparable with that of
operated wild type (255 cells, n=2) (Fig. 6D) and un-operated wild
type embryos (see Figs. 5E, F). Moreover, embryos in which ﬂow was
partially blocked showed an intermediate phenotype (327 cells,
n=3). These data supports that the cardiomyocyte increase observed
in the hozmutant ventricle depended on the elevated cardiac pressure.
Because the mechanical blockade was not a perfectly successful
method due to occasional recovery of crashed blood vessel, we further
performed a pharmacological blockade of blood ﬂow. In zebraﬁsh,
reagents such as 2,3-butanedione monoxime (2,3-BDM), which
blocks myoﬁbrillar ATPase, was used to reduce the heartbeat (Bart-
man et al., 2004; Auman et al., 2007). In medaka embryo, the reagent
affected the heartbeat at higher concentrations than that for zebraﬁsh.
At the condition we used, the ventricle was completely silent, but the
atrium occasionally beat at a very slow rate in some embryos. Under
this condition, almost all embryos survived in a healthy condition up
to 3 days from stage 32 to 37 (Figs. 6F, G). In the hoz embryos treated
with 2,3-BDM, the morphology of the ventricle was apparently
smaller than the untreated hoz ventricle and similar to that of wild
type (Figs. 6F, G). The number of cardiomyocytes was comparable
with that of wild type embryos treated with the reagent (Figs. 6H–J).
Intriguingly, the lack of concentric growth in the hoz ventricle was
also rescued by the decreased cardiac pressure (Figs. 6E, I), suggestingof the ventricle size. The surface areas of wild type (WT) and hozmutant ventricles were
, ventricle; A, atrium. (B) Increase in ventricular surface area in hozmutant. Calculation
o the equation described in the Methods section. Data are presented as the mean±SEM.
ages of wild type and hozmutant hearts, in which the labeled BrdU during stage 34–35
ell count was performed on the confocal images to exclude the labeling in non-muscle
. Statistical signiﬁcance was tested by the use of Student's t-test. **Pb0.1 (n=11 for wt,
e Tg (cmlc2:DsRed2-nuc) at stage 37. These pictures are reconstructed confocal images,
icular cardiomyocytes using the transgenic line. Cell counting was performed on the
using Student's t-test. NS, statistically not signiﬁcant at P=0.01 (n=5 for WT and hoz,
6 for hoz at stage 38). (G, H) Induction of bnp and bmp10b expression in response to the
sion of brain natriuretic peptide (bnp) at stage 37 and bmp10b at stage 34 in the mutant
the expression levels of bnp, bmp10b, ef1α, and amhc, in wild type (W) and hozmutant
the hoz heart. The number of PCR ampliﬁcation cycle were 28 cycles for amhc and bnp,
ts 50 μm in (C) and (E), and 100 μm in (G).
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and that the increased cardiac pressure impairs the proper chamber
growth.
In spite of the rescue of hoz phenotypes, the 2,3-BDM treatment
signiﬁcantly reduced the cardiomyocyte proliferation in the wild type
embryos (Fig. 6J). This raises possibilities that the cardiac pressure is a
necessary driving force to support the cardiomyocyte proliferation or
that 2,3-BDM affected the cell proliferation by a side effect that is
independent of the cardiac pressure. Considering the result of bloodvessel operation and the healthy heart development including the
concentric chamber growth in the presence of 2,3-BDM, the former
possibility seems to be more plausible than the side effect of 2,3-BDM.
To further examine the causal relation between the cardiac
pressure, cardiomyocyte increase, and the induction of bmp10, we
looked at the expression of bmp10b in the embryos in which the
cardiac pressure was lowered by the 2,3-BDM treatment (Figs. 6K, L).
The bmp10b expression was apparently reduced in embryos treated
with 2,3-BDM (Fig. 6L; n=8). The data supports that the bmp10
Fig. 6. Inﬂuence of elevated cardiac pressure on cardiomyocyte proliferation. (A–C) Outline of the blood vessel blockage experiment. In medaka embryo at stage 32, the venous blood
inﬂows into the sinus venosus (SV) through 3major veins, i.e., the 2 common cardinal veins (CCV) and the marginal vein (MV), which run on the surface of the yolk (A) (Fujita et al.,
2006). By mechanically crushing these veins (arrowheads in A and B), the blood ﬂow into the heart was blocked (C). (D, E) Visualization of cardiomyocytes in the operated embryos.
Cardiomyocytes of wild type (D) and hoz mutant (E) embryos at stage 37 were visualized by the Tg (cmlc2:DsRed2-nuc). These pictures were reconstructed from confocal images,
and only approximately half of the cardiomyocytes are visible. Respective right-side panels show the confocal optical sections through the center of the ventricle. (F, G) Appearance
of wild type (F) and hoz (G) hearts treated with the 2,3-BDM. (H, I) Cardiomyocytes in the BDM-treated wild type (H) and hoz (I) embryos at stage 37. These pictures were
reconstructed from confocal images, and the respective right-side panels show the confocal optical sections. (J) Quantiﬁcation of the number of cardiomyocytes in embryos treated
with the 2,3-BDM. Data are presented as the mean±SEM. Statistical signiﬁcance was tested by use of Student's t-test. *Pb0.01. N.S., not signiﬁcant. (K, L) Down-regulation of
bmp10b in the hoz embryos treated with 2,3-BDM. The induction of bmp10b in the hoz embryos was suppressed (n=8; compare with Fig. 5G). The 2,3-BDM treatment did not
induce the bmp10b expression in wild type embryos (n=5). OD, oil droplet; V, ventricle; A, atrium. The scale bar represents 200 μm in (A) and (B), 100 μm in (C), (F) and (K), and
50 μm in (D). The images in (D, E, H, I) are at the same magniﬁcation.
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Taken together, our results suggest that Bmp10, which has been
suggested to promote the cardiomyocyte proliferation in mammals,
may act as a mediator for the cardiomyocyte increase in the hoz
mutant in response to the elevated cardiac pressure.Discussion
The heart begins to function long before its formation is complete.
It is known that cardiomyocytes are produced almost exclusively
during development, and hence it has been thought that the number
39Y. Taneda et al. / Developmental Biology 340 (2010) 30–40of cardiomyocytes is simply determined according to the genetic
program. In this study, by analyzing the medaka vmhc mutant, hoz,
we demonstrated that the cardiomyocyte number is inﬂuenced by
elevated cardiac pressure presumably through the induction of
Bmp10, a potent mitogenic factor for cardiomyocytes. Our results
suggest the presence of a compensatory mechanism that modulates
the production of cardiomyocyte in response to an altered physio-
logical condition, which could also be at play in response to stressed
conditions even in postnatal stages.
Later occurring increase of cardiomyocyte number in the hoz mutant
The analysis of zebraﬁsh mutations has suggested a relationship of
cardiomyocyte dysfunction and resulting hemodynamic stress and/or
elevated cardiac pressure with heart morphogenesis (Sehnert et al.,
2002; Xu et al., 2002; Berdougo et al., 2003; Rottbauer et al., 2006;
Auman et al., 2007). Though these mutations cause heart dilation, the
number of cardiomyocytes has not been extensively addressed. Only
for the haf mutant, in which the vmhc gene is disrupted, it has been
reported that the number of cardiomyocytes was not altered (Auman
et al., 2007), which is in contrast with our analysis of the medaka
vmhc mutant, hoz. The reason for this difference may be due to the
stages analyzed. In zebraﬁsh, the heart looping is completed at 2 days
post fertilization (dpf), whereas the looping occurs at 3 dpf in medaka
ﬁsh among the 8–9 days of embryonic development (Fig. 1C). Though
the number of cardiomyocytes in the hafmutant was counted at 2 dpf
(Auman et al., 2007), we did not see any difference betweenwild type
and hoz embryos at the corresponding medaka stage 30 (Fig. 5F). The
difference became apparent only in the successive stages. Further-
more, as the hoz mutant can survive more than 5 days after stage 30,
the slow development and longer progression of the phenotype could
make the phenotype clear in medaka ﬁsh.
Cell-surface extension and cell-shape abnormality in the hoz mutant
On the other hand, a similar phenotype to the zebraﬁsh hafmutant
was also observed in cell-shape and surface-area extension (Supple-
mentary Fig. 2D). Though we did not analyze the detail of this
phenotype, it seemed that the surface area was slightly extended in
the mutant cardiomyocytes. Considering the 1.6-fold increase in
cardiomyocyte proliferation and 2-fold increase of the number of
surface cells due to the lack of concentric growth, the surface-area
extension of each cardiomyocyte would be expected to be 1.75-fold in
the hoz mutant for attaining the 5.6-fold increase in the total
ventricular surface area. This calculation corresponds to the measured
cell-surface extension, 1.8-times, found in the zebraﬁsh haf mutant
(Auman et al., 2007), suggesting that a similar extent of cell-surface
extension occurs in the hoz mutant.
Concentric growth of cardiac chambers
Another phenotype that we found in the medaka hoz mutant was
the lack of concentric chamber growth of the ventricle. It has been
suggested that a signal emanating from the endocardium regulates
the concentric chamber growth (Mably et al., 2006). Within
cardiomyocytes, the cardiomyocyte cell polarity such as the oriented
formation of myoﬁbers plays an important role in heart morphogen-
esis and concentric chamber growth (Sultana et al., 2008). Moreover,
an intrinsic signaling mechanism that associates with the contractile
machinery and/or signaling scaffold such as the Titin complex might
also be involved in the concentric growth of chamber (Granzier and
Labeit, 2005; Linke, 2008). Therefore, a proper heartbeat, sarcomere
function and/or orientation could be required for mediating the signal
to direct the dimension of chamber growth.
However, our experiments blocking the blood ﬂow suggested
that the hoz ventricle retains the ability for the concentric growthand that it can perform a considerable extent of concentric growth
when the cardiac pressure was decreased. This suggests that the
concentric growth can occur in the absence of the myoﬁber and
heart beating. Possibly, the concentric growth in the hoz mutant
may be suppressed by the improper cell polarity caused by a strong
mechanical overload toward the planar direction and/or the
shortage of cardiomyocyte supply to sufﬁciently support the increase
of chamber growth.
Another interesting phenotype of hoz mutant was that the lack of
contractile apparatus and inability of ventricular beating did not affect
the cardiomyocyte maturation itself, suggesting that the cardiomyo-
cyte maturation is independent from the heart beating and elevated
cardiac pressure. The cardiomyocyte maturation as a muscle cell
might be regulated by other factors such as the Nkx2.5, Tbx5, and
Mef2c, which control cell differentiation. Consistent with this idea, the
expression of these genes was not affected in the hoz mutant.
Epigenetic regulation of cardiomyocyte number in response to elevated
cardiac pressure
An important implication made from our analysis is that
cardiomyocyte production during development is determined not
only by genetic program, but also by epigenetic conditions. The
number of cardiomyocytes increased as much as 1.6-fold by the
increased blood pressure. Such a ﬂuctuation in cardiomyocyte
number generated during development may affect the heart function
throughout the life of an animal (Leu et al., 2001). Thus, we suggested
that the cardiomyocyte proliferation in response to epigenetic
inﬂuences is a major cause of increased cardiomyocytes; however, it
has recently been proposed in zebraﬁsh as well as amniotes that
cardiomyocytes differentiate from the second heart ﬁeld (SHF) to
support the cardiomyocyte number increases during cardiac looping
(de Pater et al., 2009). So, there is a possibility that the number of cell
in the ventricle increases by recruitment and differentiation of cells
from the SHF. However, our quantiﬁcation of cell proliferation at stage
34–35 showed 1.4-fold increase of BrdU-positive cardiomyocytes,
which is comparable to the actual increase of cardiomyocytes (stage
34, 1.3 fold; stage 38, 1.6-fold) revealed by the Tg (cmlc2:DsRed2-nuc).
In addition, the ventricle enlargement in the hoz becomes apparent
after the heart looping. Therefore, it is likely that the observed
cardiomyocyte increase in the hozmutant may mainly reﬂect the cell
proliferation within the ventricle.
Importantly, we observed that Bmp10 was induced in the hoz
ventricle. Though we do not have a direct functional test of medaka
Bmp10, the BMP10 function for cardiomyocyte proliferation has been
well documented in mammals (Chen et al., 2004; Pashmforoush et al.,
2004). More recently, up-regulation of Bmp10 expression in the
hypertrophic rat heart has been observed, and its implication in
adaptive myocardial hypertrophy has been made (Nakano et al.,
2007). From these and other studies in mammals, it is highly probable
that Bmp10 has a function in supporting excess cardiomyocyte
proliferation of the hozmutant. Other than Bmp10, a number of other
proteins such as the Reptin and Pontin (Rottbauer et al., 2002), L-type
calcium channel (Rottbauer et al., 2001), and PDGF (Lien et al., 2006)
also have functions for controlling cardiomyocyte proliferation.
However, since Bmp10 is the only molecule whose expression was
induced in the hoz mutant, the Bmp10 expression in response to
stressed conditionsmay play a compensatory role that tunes the heart
formation. Hence, any mis-regulation of the mechanism during
development could lead to congenital heart disorders (Bartman et
al., 2004), and it could also affect the cardiomyocyte proliferation
(Bergmann et al., 2009) and hypertrophic growth in cardiomyopa-
thies (Akazawa and Komuro, 2003; Oka et al., 2007; Ransom and
Srivastava, 2007) even in the postnatal periods.
Considering the function of Bmp10 protein in promoting cardio-
myocyte proliferation (Chen et al., 2004), induction of bmp10 in
40 Y. Taneda et al. / Developmental Biology 340 (2010) 30–40response to increased blood pressure may explain the aberrant
production of cardiomyocytes in the hoz ventricle.
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